These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10388999)

  • 1. Hypersensitivity to regular and intermediate, but not to crystallized, insulin as an aggravation factor for underlying bulimia nervosa in a patient with type 1 diabetes.
    Itoh M; Uchimura K; Makino M; Kobayashi T; Kakizawa H; Nagata M; Fujiwara K; Kato S; Itoh Y; Nagasaka A
    Diabetes Care; 1999 Jul; 22(7):1221-4. PubMed ID: 10388999
    [No Abstract]   [Full Text] [Related]  

  • 2. [The clinical efficacy of Russian preparations of VO-S insulin and porcine insulin from Western firms in patients with diabetes mellitus type 1].
    Alekseeva OP; Shalenkova MA; Bodiakshina MN
    Voen Med Zh; 1998 May; 319(5):60-2. PubMed ID: 9680841
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.
    Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H
    J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalised insulin oedema after intensification of treatment with insulin analogues.
    Adamo L; Thoelke M
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23429012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin allergies].
    Sola-Gazagnes A
    Soins; 2007 Apr; (714 Suppl):S2, S4-5. PubMed ID: 17569273
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin degludec: The new standard long acting insulin analogue for people with type 1 diabetes? [Letter to the Editor].
    Merchante-Alfaro AÁ; Pérez-Naranjo S; Abellán-Galiana P; Rubio-Puchol O
    Endocr J; 2016 Apr; 63(4):411-2. PubMed ID: 26961339
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs.
    Rossetti P; Porcellati F; Bolli GB; Fanelli CG
    Diabetes Care; 2008 Feb; 31 Suppl 2():S113-20. PubMed ID: 18227470
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin analogues for recurrent severe hypoglycaemia.
    Knip M
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):529-30. PubMed ID: 24794702
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin degludec products approved for diabetes.
    Traynor K
    Am J Health Syst Pharm; 2015 Nov; 72(21):1834. PubMed ID: 26490811
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypoglycemia in diabetic children].
    Tupola S; Rajantie J
    Duodecim; 2000; 116(2):125-31. PubMed ID: 11764469
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 17. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus.
    Dixon AN; Bain SC
    BMJ; 2005 Feb; 330(7489):455. PubMed ID: 15731143
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
    Pedersen-Bjergaard U; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):553-61. PubMed ID: 24794703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog).
    Roper NA; Bilous RW
    Diabet Med; 1998 Dec; 15(12):1063-4. PubMed ID: 9868982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New formulation with improved pharmacokinetics].
    Walter M
    MMW Fortschr Med; 2015 Feb; 157(3):69. PubMed ID: 25743680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.